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INTRODUCTION
HIV-1 continues to be a major global public health issue, having 
claimed more than 25 million lives over the past three decades. It is 
estimated that 34 million individuals around the world are currently 
living with HIV-1. Standard treatment for HIV-1 infection is highly 
active antiretroviral therapy, which can reduce plasma viral loads to 
undetectable levels for years at a time.1–3 During this time, however, 
HIV-1 persists in various cellular reservoirs, and discontinuation of 
antiretroviral therapy can lead to rapid rebound of viral loads caus-
ing renewed disease progression toward AIDS.4–6 While antiretrovi-
ral therapy is effective at reducing viral load and maintaining CD4+ 
T-lymphocyte counts, strict adherence by the individual is required 
to maintain effectiveness; however, side effects of antiretroviral 
therapy can be severe, long-term complications can develop, and 
HIV-1 resistance to the antiretroviral regimen can also develop.7–10
A promising alternative approach is cell-delivered gene therapy, 
in which anti–HIV-1 agents are delivered into target cells with the 
intention to interfere with the HIV-1 life cycle. Infusion of the geneti-
cally engineered HIV-1–resistant cells to patients has the potential to 
control HIV-1 infection, slow disease progression, repair damage to 
the immune system, and reduce reservoirs of infected and latently 
infected cells.11–13 Other approaches that have been tested include 
vaccines, immunotherapy, adoptive immunotherapy, and vectored 
immunoprophylaxis. HIV-1 gene therapy has been applied target-
ing early life cycle steps before integration, such as HIV-1 binding, 
fusion/entry, and reverse transcription, or later steps, including inte-
gration, transcription, translation, maturation, or virion assembly.12 
Some of these approaches were tested in clinical trials using gene 
agents such as silencing dominant negative rev, env antisense RNA, 
ribozymes, Rev response element (RRE) decoy, fusion inhibitors, 
short hairpin RNA, and zinc finger nucleases.12–14
One promising strategy of preventing HIV-1 entry is based on 
suppression of the HIV-1 coreceptor, C-C chemokine receptor type 5 
(CCR5). Genetic and molecular studies on human populations have 
demonstrated that individuals homozygous for a defective CCR5 
gene, CCR5∆32, are protected from HIV-1 infection,15–18 and hetero-
zygous individuals with a 50% reduction in the expression level of 
CCR5 on the cell surface have a substantially reduced rate of disease 
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Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are resistant to the virus. We have 
engineered a novel self-inactivating lentiviral vector, LVsh5/C46, using two viral-entry inhibitors to block early steps of HIV-1 cycle. 
The LVsh5/C46 vector encodes a short hairpin RNA (shRNA) for downregulation of CCR5, in combination with the HIV-1 fusion 
inhibitor, C46. We demonstrate here the effective delivery of LVsh5/C46 to human T cell lines, peripheral blood mononuclear cells, 
primary CD4+ T lymphocytes, and CD34+ hematopoietic stem/progenitor cells (HSPC). CCR5-targeted shRNA (sh5) and C46 peptide 
were stably expressed in the target cells and were able to effectively protect gene-modified cells against infection with CCR5- and 
CXCR4-tropic strains of HIV-1. LVsh5/C46 treatment was nontoxic as assessed by cell growth and viability, was noninflammatory, 
and had no adverse effect on HSPC differentiation. LVsh5/C46 could be produced at a scale sufficient for clinical development and 
resulted in active viral particles with very low mutagenic potential and the absence of replication-competent lentivirus. Based on 
these in vitro results, plus additional in vivo safety and efficacy data, LVsh5/C46 is now being tested in a phase 1/2 clinical trial for 
the treatment of HIV-1 disease.
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progression.19,20 Homozygous CCR5∆32 is a stable genetic trait with 
a frequency of 1.4% in the Caucasian population.21 These individuals 
are healthy apart from the potential for increased pathogenicity of 
West Nile Virus infection.22
A functional cure for HIV-1 infection has been demonstrated 
recently in the “Berlin patient” case, where a HIV-1–positive individ-
ual, with concurrent acute myeloid leukemia, was treated by trans-
plant of homozygous CCR5Δ32 allogeneic hematopoietic stem/
progenitor cells (HSPC).23 Reconstitution of the immune system with 
cells protected from HIV-1 infection led to substantial attenuation of 
HIV-1 replication and an increase in CD4+ T-cell counts. The CCR5∆32 
donor cells nearly completely replaced the recipient cells within 61 
days, and the patient’s viral load has remained undetectable in the 
absence of antiretroviral therapy.24 However, due to the low preva-
lence of homozygous CCR5∆32 genotype and limited availability 
of donors, more practical approaches are currently being sought. 
Blocking virus–CCR5 interaction by inhibiting or eliminating CCR5 
expression is being investigated by a number of groups that include 
the use of ribozymes directed to CCR525–28, single-chain intrabod-
ies,27,29 RNA interference,30–37 and zinc finger nuclease.38–40
A specific short hairpin RNA to CCR5 was previously demon-
strated to effectively inhibit CCR5 expression and thereby protect 
primary human CD4+ T lymphocytes from CCR5-tropic HIV-1 infec-
tion in culture.31,41 Expression of this potent anti-CCR5 shRNA (CCR5 
shRNA1005, or here termed sh5) was subsequently optimized 
using the human H1 promoter in a lentiviral vector to stably inhibit 
HIV-1 replication.42 The H1-CCR5 shRNA 1005 vector was shown to 
be noncytotoxic and effective in stable downregulation of CCR5 
in human primary peripheral blood mononuclear cells (PMBCs) in 
vitro,42 and in vivo using the humanized bone marrow–liver–thymus 
(BLT) mouse model36 as well as in nonhuman primates introduced 
through hematopoietic stem cell transplant.41
C46 is an HIV-1 entry inhibitor derived from the C-terminal hep-
tad repeat of HIV-1 gp41 modified to be expressed on the cell sur-
face. C46, like other gp41-derived C peptides, blocks HIV-1 fusion 
to the cellular membrane by interacting with the N-terminal coiled-
coil domain of the HIV-1 gp41 intermediate structure and prevent-
ing the six-helix bundle formation. In vitro studies have shown that 
membrane-anchored C46 protein effectively protects cells against 
a broad range of HIV-1 isolates by blocking entry of the virus to the 
target cells.43–46 The safety of C46 has been tested previously in a 
phase 1 clinical trial in which autologous T cells, transduced with 
a retroviral vector expressing C46, were infused into HIV-1–positive 
patients without adverse effects.47
It is well established that HIV-1 can rapidly develop resistance to 
monotherapy by emergence of point mutations in virus variants, 
whereas combined therapy shows better clinical outcome.10,48–50 
In patients treated with CCR5 inhibitors, R5 variants of HIV-1 can 
evolve to use the blocked receptor. In addition, there are X4-tropic 
strains of HIV-1 that use the alternate coreceptor, CXCR451–53. The 
role of these X4 viruses in HIV-1 pathogenesis is as yet unclear54–57; 
however, effective genetic therapeutic applications for HIV-1 infec-
tion will likely require combinations of multiple reagents directed 
against HIV-1.
In the present study, we have developed a self-inactivating (SIN) 
lentiviral vector construct for gene transfer, LVsh5/C46, to express a 
combination of two anti–HIV-1 genes: sh5, an shRNA to the HIV-1 
coreceptor CCR5, and C46, the antiviral fusion inhibitor peptide. 
We assessed expression of the anti–HIV-1 transgenes in cell culture 
and any impact on viability or phenotype and efficacy of inhibit-
ing HIV-1 infection. We show here the ability of LVsh5/C46-modified 
cells to stably downregulate CCR5 and express C46. LVsh5/C46 was 
well tolerated when introduced into hematopoietic cells based on 
their viability, ability to proliferate, differentiate, and retain their 
normal phenotype. Moreover, we show that treatment of hemato-
poietic cells with LVsh5/C46 provides protection from the establish-
ment of HIV-1 infection and replication from multiple strains, clades, 
and tropisms of HIV-1.
ReSUlTS
Engineering and production of LVsh5/C46 vector
To construct the LVsh5/C46 plasmid, we utilized FG12, a SIN lenti-
viral plasmid that is based on the HIV-1 backbone with modified 5′ 
and 3′ HIV-1 long terminal repeats.31 First, the HIV-1 fusion inhibi-
tor C4643 was introduced into the FG12 plasmid downstream of 
the human Ubiquitin C (UbC) promoter, replacing the enhanced 
green fluorescent protein sequence. Next, a previously character-
ized shRNA against CCR5 (1005), driven by the human H1 RNA poly-
merase III promoter,41 was inserted upstream of the UbC promoter 
(Figure 1a). The two viral-entry inhibitors, incorporated into a single 
construct, were then tested in vitro for their ability to be expressed 
in target cells, their effect on the treated cells, and their potency in 
suppressing HIV-1 replication.
Small-scale production of LVsh5/C46 viral vector was used during 
the initial characterization studies followed by preclinical testing of 
LVsh5/C46 preparations generated using methodology and pro-
cedures consistent with good laboratory practice (GLP) and good 
manufacturing practice (GMP). Comprehensive testing for purity, 
safety, and functionality was conducted for a 251 ml pilot lot of GLP 
vector and two large-scale batches (25 l each) of GMP-grade vec-
tor. Small-scale virus production routinely yielded a titer of 3–5 × 106 
infectious viral particles per milliliter (ivp/ml), whereas GLP grade 
and GMP-grade productions of LVsh5/C46 vector yielded 8 × 107 ivp/
ml and 1–2 × 108 ivp/ml, respectively. LVsh5/C46 virus particles were 
introduced into various cell lines, PBMCs, CD4+ T lymphocytes, and 
hematopoietic stem cells for detailed preclinical characterization.
Expression of LVsh5/C46 in hematopoietic cells
Gene delivery of the dual anti–HIV-1 agents was first assessed in tar-
get cells transduced with small-scale vector preparations of LVsh5/
C46. PBMCs and the CCR5-expressing T cell line Molt4/CCR5 were 
transduced with LVsh5/C46, and cell-surface expression of C46 and 
CCR5 was assessed by fluorescence-activated cell sorting (FACS) 
after 4 days. At a multiplicity of infection (MOI) of 1, 39.35% of PBMCs 
(33.9 + 5.45%) were transduced as determined by expression of the 
C46 peptide (Figure 1b). At this MOI, CCR5 expression was reduced 
from 58.3% in control cells (56.3 + 2.03%) to 19.65% in LVsh5/C46 
transduced cells (14.2 + 5.45%) (Figure 1b). When Molt4/CCR5 cells 
were transduced at an MOI of 2, 92.9% of the cells expressed C46 
peptide, and CCR5 expression was decreased from 86.98 to 17.94% 
posttransduction (Figure 1b). These results demonstrated success-
ful delivery of LVsh5/C46 vector into cells, ability of the modified 
cells to express sh5 short hairpin RNA and C46 peptide, and suc-
cessful downregulation of CCR5.
To assess longer-term stability of the integrated LVsh5/C46 in the 
modified cells, the T cell line CEM.NKR.CCR5 was transduced with 
LVsh5/C46, and a time course of CCR5 and C46 expression was ana-
lyzed by flow cytometry. As shown in Figure 1c, after 2 months in 
culture, 68.5% of cells maintained C46 peptide expression (48.8 + 
19.7%), and CCR5 expression was decreased from 98.5% on day 0 to 
34.1% at week 8, indicating that LVsh5/C46 vector persisted in the 
cells over time and effectively expressed the therapeutic anti–HIV-1 
genes.
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To quantify LVsh5/C46 gene transfer, PBMCs were transduced 
with increasing doses of LVsh5/C46 followed by evaluation of vector 
copy number and RNA transcript synthesis in the transduced cells. 
Transduction at MOI of 1 resulted in one copy of LVsh5/C46 per cell, 
while higher doses of LVsh5/C46 vector (MOIs of 5 and 10) led to an 
average of 1.5–2 copies of LVsh5/C46 viral DNA per cell (Figure 1d). 
Furthermore, we observed a dose-dependent increase in C46 RNA 
synthesis in response to elevated LVsh5/C46 dose as quantified by 
reverse transcription–quantitative PCR (RT-qPCR) (Figure 1e). This 
data demonstrated the ability to define the preferred dose of LVsh5/
C46 vector delivered into human primary cells by correlating MOI 
with the integrated vector copy number and the RNA transcripts of 
C46 transgene.
To further evaluate the therapeutic potential of LVsh5/C46, we 
purified CD4+ T lymphocytes and CD34+ HSPC and demonstrated 
that the intended target cells were genetically modified in vitro to 
produce the anti–HIV-1 gene agents. Purification of CD4+ T lympho-
cytes was achieved by isolation of PBMCs, followed by a CD8 deple-
tion step and CD3/CD28 stimulation and activation. The purification 
process yielded purity of 88.6% CD4+ cells (Figure 2a, lower right 
panel). Human CD34+ HSPC were isolated from granulocyte colony-
stimulating factor mobilized peripheral blood using CliniMACS with 
Figure 1 Expression of the dual-therapeutic anti–HIV-1 genes in T cell lines and in human primary cultures. (a) Schematic representation of LVsh5/
C46 lentiviral vector. The CCR5 shRNA (1005)/FG12 vector (previously described)41 was digested by NdeI/XhoI to excise a fragment containing CCR5 
shRNA (sh5) under the human H1 RNA polymerase III promoter. The insert was cloned into the same sites in an FG11F vector encoding membrane-
anchored C4643, under the Ubiquitin C promoter (UbC). Other components of the vector include 5′ and 3′ modified HIV-1 long terminal repeats (LTRs), 
a central polypurine tract (cPPT), and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). (b) PBMCs and Molt4/CCR5 cells were 
transduced with LVsh5/C46 at MOI of 1 and 2, respectively, in triplicate, and expression of sh5 and C46 was assessed by flow cytometry. CCR5 shRNA 
(sh5) expression was demonstrated by downregulation of CCR5 expression evidenced by CD195 staining. Cell-surface expression of C46 was detected 
by staining with 2F5 antibody. (c) The T cell line CEM.NKR.CCR5 was transduced with LVsh5/C46, and the expression of CCR5 and C46 was similarly 
assessed over 8 weeks in culture by flow cytometry. (d, e) Quantification of integrated LVsh5/C46 DNA and LVsh5/C46-mediated C46 mRNA synthesis 
in transduced PBMCs. Cells were treated with LVsh5/C46 at MOIs of 1, 5, and 10 (in duplicate), resulting in transduction efficiencies of 35, 62.5, and 74% 
(respectively) at 4 days postinfection as assessed by flow cytometry (data not shown). Genomic DNA and RNA were isolated at 8 days posttransduction. 
C46 DNA copy number per cell was determined by quantitative PCR and was normalized to β-globin (d). C46 RNA transcript levels were measured 
by RT-qPCR using C46 primers and were normalized to β2-microglobulin mRNA as a measure of relative C46 expression (e). PBMC, peripheral blood 
mononuclear cell; shRNA, short hairpin RNA.
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CD34-microbeads as positive selection, which yielded purity of over 
99% (Figure 2b). Purified CD4+ T lymphocytes and CD34+ HSPC cells 
were then treated with LVsh5/C46 vector at increasing MOIs (0.5–
10), and the cell-surface C46 expression was determined by FACS 
analysis. A dose-dependent increase in the number of cells express-
ing C46 was observed in response to increasing doses of LVsh5/C46 
(Figure 2c,d). Transduction efficiency in CD4+ cells ranged between 
10 and 50% and between 2 and 15% in CD34+ cells. The doses of 
LVsh5/C46 chosen for the subsequent studies were MOI of 1 for 
CD4+ transduction and MOI of 5 for CD34+ HSPC. In large-scale 
experiments using GMP-grade LVsh5/C46 vector, improved trans-
duction efficiencies were observed. Over 40% transduction effi-
ciency was obtained in CD4+ T lymphocytes transduced at MOI of 1 
and in CD34+ HSPC transduced at MOI of 5 (Figure 2e).
To further evaluate the degree of gene transfer in the transduced 
cells, CD4+ and CD34+ cells were treated with GMP-grade LVsh5/
C46 at MOIs of 1 and 5, respectively. Genomic DNA was extracted, 
and quantitative PCR was performed to determine C46 copy num-
ber per cell. As shown in Figure 3a, an average of 2–2.5 copies of 
integrated LVsh5/C46 vector DNA was observed in CD4+ and CD34+ 
transduced cells. Expression of CCR5 shRNA (sh5) was also detected 
in the transduced CD4+ and CD34+ using RT-qPCR (Figure 3b). Taken 
together, these results validate the ability of LVsh5/C46 to geneti-
cally modify hematopoietic target cells, by stable integration and 
sustained expression of C46 and sh5.
LVsh5/C46-modified HSPC retain their full differential capacity
To determine whether CD34+ HSPC transduced with LVsh5/C46 
could maintain their differentiation capacity, colony-forming assays 
were performed. CD34+ cells were transduced with a high dose of 
LVsh5/C46 (MOI of 10), and after 2 weeks in methylcellulose culture, 
Figure 2 Introducing LVsh5/C46 vector into target cells. (a) Human CD4+ T lymphocytes were isolated from PBMCs by CD8 depletion followed by 
selection and expansion using CD3/CD28 beads. Cells were stained with CD4, CD3, and CD8 antibodies and analyzed by flow cytometry. Purified CD4+ 
T-lymphocyte cells are shown as CD4+/CD3+/CD8− fraction in the lower right panel. (b) CD34+ HSPC were isolated from G-CSF mobilized peripheral 
blood, using CD34+ microbeads. Positive fraction was stained with CD34 antibody and analyzed by flow cytometry. (c, d) Purified cells were treated 
with LVsh5/C46 at the increasing doses (MOIs as indicated), in triplicate, and the percentage of (c) C46-expressing CD4+ cells and (d) CD34+ cells was 
determined by flow cytometry. (e) Purified CD4+ T lymphocytes and CD34+ HSPC cells were treated with GMP-grade LVsh5/C46 at MOI of 1 and 5, 
respectively, and LVsh5/C46 transduction was analyzed by flow cytometry, measuring the percentage of cells expressing cell-surface C46. G-CSF, 
granulocyte colony-stimulating factor; GMP, good manufacturing practice; HSPC, hematopoietic stem/progenitor cell; MOI, multiplicity of infection; 
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the colony-forming units (CFU) were enumerated and characterized. 
Quantification of colonies of erythroid (CFU-E), myeloid (CFU-GM), 
and multiple lineage origin (CFU-GEMM) generated from LVsh5/
C46-transduced cells showed no significant difference compared to 
untransduced cells (Figure 4a). Similar results were obtained when 
HSPC were transduced with either singular anti–HIV-1 genes (C46 
or sh5) or the dual agents (LVsh5/C46). Transduced cells generated 
comparable numbers of differentiated colonies, with no obvious 
effects of either C46 or sh5 expression (Figure 4b–d). These findings 
demonstrate that LVsh5/C46-modified HSPC retain their capacity 
for multilineage hematopoietic differentiation in vitro, without lin-
eage skewing, even at a relatively high dose of LVsh5/C46.
LVsh5/C46-modified cells retain their normal phenotype
To investigate the effect of LVsh5/C46 on the phenotype of the 
treated cells, PBMCs were treated with LVsh5/C46 at MOIs of 1 and 
10, and analyzed after 7–8 days in culture. We first determined 
whether apoptosis was induced in LVsh5/C46-modified cells. 
Similar activity of Caspase 3/7 was found in transduced PBMCs 
compared to untransduced cells, at low and high MOIs of LVsh5/
C46, indicating that neither LVsh5/C46 transduction nor expression 
of sh5 or C46 induced programmed cell death (Figure 5a). We then 
assessed the influence of LVsh5/C46 on cell growth as measured 
by the number of metabolically active cells and observed compa-
rable activities in untreated and LVsh5/C46-treated cells (Figure 
Figure 3 LVsh5/C46 genomic DNA integration and LVsh5/C46-mediated shRNA expression in hematopoietic cells. CD4+ T lymphocytes and CD34+ HSPC 
were transduced with LVsh5/C46 at MOIs of 1 and 5, respectively. (a) Genomic DNA was isolated from the transduced cells, and C46 DNA copy number 
normalized to β-globin was determined by quantitative PCR. (b) RNA was extracted from the transduced cells, and CCR5 shRNA transcript level was 
determined by RT-qPCR using sh5 primers and was normalized to the expression of RNU38B microRNA. HSPC, hematopoietic stem/progenitor cell; 
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Figure 4 LVsh5/C46-modified CD34+ HSPC maintain their multilineage hematopoietic differentiation potential. CD34+ HSPC from three healthy 
donors were transduced with the indicated lentiviral vectors, and 2 weeks posttransduction, methylcellulose colony-forming unit (CFU) assays 
were performed. Colonies were enumerated for CFU erythrocyte (CFU-E); CFU granulocyte/monocyte (CFU-GM), and CFU granulocyte/erythrocyte/
monocyte/megakaryocyte (CFU-GEMM) and compared to untransduced HSPC. (a) CD34+ cells were transduced with LVsh5/C46 vector at MOI of 10, 
and the relative colony counts were plotted against untransduced cells. (b–d) CD34+ cells were transduced with lentiviral vectors expressing sh5 alone, 
sh5 fused to enhanced green fluorescent protein reporter gene, C46 alone, or LVsh5/C46 (sh5/C46), and CFU assays were performed. Colonies from 
the lineages (b) CFU-GM, (c) CFU-E, and (e) CFU-GEMM were scored, and the relative colony counts were plotted against untransduced cells. HSPC, 
hematopoietic stem/progenitor cell; MOI, multiplicity of infection.
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5b). In addition, PBMCs were treated with LVsh5/C46 or with len-
tiviral vectors expressing the single genes (sh5 or C46), and cell 
viability was assessed and enumerated for a period of 12 days (see 
Supplementary Figure S1a,b). Proliferation was found to be similar 
between transduced and untransduced cells with no impact on 
viability.
To further examine the cellular response to LVsh5/C46, the lev-
els of the cytokines interferon γ, interleukin-6, and tumor necrosis 
factor α were measured in transduced PBMCs and control cells. 
As shown in Figure 5c–e, there were no significant differences in 
the intracellular production of these proinflammatory cytokines 
between LVsh5/C46-treated PBMCs and untreated cells, indicating 
that inflammatory signaling was not activated by either viral trans-
duction or LVsh5/C46-mediated expression of sh5 or C46.
Stability of LVsh5/C46 vector in transduced cells
To evaluate the stability of the viral vector in modified cells, VERO 
cells (monkey kidney epithelial) were transduced with LVsh5/C46, 
and the structure and integrity of the integrated vector was evalu-
ated. Genomic DNA extracted from the transduced cells and sub-
jected to southern blot analysis revealed two major forms of the 
integrated LVsh5/C46 DNA: a nonspliced 3.8 kb viral vector and the 
anticipated spliced form of 3 kb, due to splicing of the UbC intron, 
Figure 5 LVsh5/C46 vector does not induce deleterious effect on cells. PBMCs from three to five healthy donors were transduced with LVsh5/
C46 (sh5/C46) at MOIs of 1 or 10 or and were compared to untransduced cells and to cells transduced with a control lentivirus vector encoding 
eGFP (enhanced green fluorescent protein) at MOI of 1. In different experiments, transduction efficiency was determined by flow cytometry to be 
15–44% at an MOI of 1 and 36–64% at an MOI of 10. Cells were assessed for apoptosis, proliferation, and inflammation; results were normalized 
to untransduced cells; and Student’s t-test was performed. (a) Apoptosis was not induced in LVsh5/C46-transduced PBMCs. Caspase 3/7 activities 
were assessed 7 days posttransduction by luminescence assay (n = 3). Staurosporine was used as a positive control. (b) LVsh5/C46 did not alter 
viability or proliferative capacity of modified PBMCs. Cells were cultured for 7 days, and proliferation rate was assessed (n = 5). IL-2 was used 
as a positive control. (c–e) Transduced PBMCs were cultured for 8 days, and the level of the cytokines (c) interferon-γ (n = 3), (d) interleukin-6 (n 
= 4), and (e) TNF-α (n = 4) was determined. Cells treated with PHA were used as positive controls. *P < 0.05 compared to untransduced cells. **P 
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as described previously58,59 (see Supplementary Figure S2a,b). 
Sequencing analysis of the 3 kb band confirmed splicing event 
within the UbC region (data not shown). Apart from the expected 
splicing, the overall structural organization of the integrated LVsh5/
C46 vector was kept intact and was genetically stable, with no rear-
rangements, duplications, insertions, or unexpected deletions.
Low risk of mutagenic potential in LVsh5/C46-modified 
hematopoietic cells
To assess the mutagenic potential of LVsh5/C46, in vitro immor-
talization assays were performed. Primary murine hematopoietic 
cells (Lin−) were cultured in the presence of LVsh5/C46 at MOIs of 
20, 40, and 80, and the incidence of cell transformation was calcu-
lated as replating frequency per vector copy number. LVsh5/C46 
vector was compared to two positive control vectors shown previ-
ously to induce in vitro immortalization.60 lv-SF, a lentiviral vector in 
SIN configuration under the control of a strong internal retroviral 
promoter of the spleen focus forming virus, and RSF91, a gamma-
retroviral vector with internal or long terminal repeat– contained 
spleen focus forming virus promoter sequences. A mock infected 
sample cultured without a viral vector served as a measure of spon-
taneous immortalization and routinely scored negative. In three 
independent experiments, transformation frequency per vector 
copy number in cells treated with LVsh5/C46 vector was strongly 
reduced compared to positive controls (see Supplementary Figure 
S3). These results demonstrate a significantly reduced risk of inser-
tional mutagenesis and genotoxicity.
No evidence of replication-competent lentivirus in LVsh5/C46-
transduced cells
To further evaluate the safety of LVsh5/C46 vector as a potential 
therapeutic agent, the risk of replication-competent lentivirus (RCL) 
development was analyzed. LVsh5/C46 is a SIN lentiviral vector, in 
which modifications to the HIV-1 long terminal repeats signifi-
cantly reduce the likelihood that RCL will develop. RCL testing has 
been performed on samples of LVsh5/C46 viral production batches 
(large-scale GLP and GMP). Five percent of the total batch volumes 
were used to inoculate C8166-45 cells, a highly infectable cell line.61 
After a culturing period of a minimum of 21 days to allow poten-
tial amplification of any RCL, the supernatants were collected and 
were incubated with fresh permissive cells. Supernatants were col-
lected for p24 ELISA to detect HIV-1 capsid protein, and genomic 
DNA was used for psi-gag PCR to detect recombination. Results from 
all batches tested showed no detectable quantities of p24 antigen 
or HIV-1 DNA, hence, confirming the absence of RCL in the LVsh5/
C46-modified cells (see Supplementary Table S1). Moreover, in a 
separate RCL assay, in which postproduction HEK293T cells were 
cocultured with the C8166-45 cell line, no RCL was detected in any 
of the LVsh5/C46 test samples, as indicated by the absence of detect-
able quantities of p24 protein and HIV-1 psi-gag recombination (see 
Supplementary Table S1). These results demonstrate that the likeli-
hood of RCL development using clinical grade of LVsh5/C46 lentivi-
ral vector is extremely low.
Modification of T cell lines with LVsh5/C46 effectively inhibits HIV-1 
replication
The ability of the LVsh5/C46 vector to confer cellular resistance from 
HIV-1 infection was evaluated by conducting HIV-1 challenge assays 
in vitro. First, the T cell line Molt4/CCR5 was transduced with LVsh5/
C46 at MOI of 5 followed by infection with CCR5 (R5)-tropic HIV-1 
strain BaL or CXCR4 (X4)-tropic strain NL4-3. Two weeks postinfection, 
the appearance of viral p24 antigen in the medium was measured, 
and the infection level of LVsh5/C46-modified cells was compared 
to untransduced control cells. As shown in Figure 6a, while untrans-
duced Molt4/CCR5 were susceptible to BaL (R5) and NL4-3 (X4) strains, 
viral infection was strongly suppressed in LVsh5/C46-modified cells, 
indicating that cells expressing LVsh5/C46 were significantly more 
resistant to HIV-1 infection compared to control cells. Similarly, when 
the LVsh5/C46-modified Molt4/CCR5 cells were infected with a dual 
R5/X4 tropic HIV-1 strain, SF2, viral titer was reduced dramatically 
relative to untransduced cells, exhibiting ~100-fold inhibition of viral 
replication (Figure 6b). This observation was consistent when trans-
duced cells were exposed to low or high dose of SF2 strain. These 
results demonstrate the ability of LVsh5/C46 to provide strong resis-
tance against R5-, X4-, and R5/X4-tropic HIV-1 strains.
We next tested the potency of the dual-therapeutic vector to 
single vectors containing either sh5 or C46 alone. Molt4/CCR5 cells 
were transduced with either LVsh5/C46 or lentiviral vectors contain-
ing sh5 or C46 genes, followed by infection with the R5-tropic strain 
BaL, and infection level was evaluated 7 and 10 days postinfection 
by p24 assay. In cells expressing either sh5 or C46 alone, BaL infec-
tion was inhibited; nonetheless, LVsh5/C46 was more effective than 
either vector expressing single agents (Figure 6c).
The Molt4/CCR5 cells were then transduced with low or high MOIs 
of sh5, C46, or LVsh5/C46 lentiviral vectors constructs, followed by 
exposure to either X4-tropic NL4-3 or R5-tropic BaL, and infection 
level was analyzed. As expected, sh5 vector was able to inhibit rep-
lication of R5-tropic but not X4-tropic strain, whereas C46 provided 
a stronger resistance against R5-tropic and X4 HIV-1–tropic strains. 
The combined LVsh5/C46 exhibited the strongest viral inhibition, 
reducing p24 concentration from 6,400 to 2 ng/ml in BaL infection 
and from 2,048 to 4 ng/ml in NL4-3. The response to higher dose of 
LVsh5/C46 resulted in the same effect (Figure 6d). Taken together, 
these results demonstrate that LVsh5/C46, as a dual anti–HIV-1 
agents in a single lentiviral construct, has additive effect compared 
to the single agents, delivering robust inhibition of a broad range 
of HIV-1 strains.
LVsh5/C46-treated PBMCs inhibit replication of R5- and X4-tropic 
HIV-1 strains
We next assessed the ability of LVsh5/C46 to provide resistance to 
primary human PBMC cultures from HIV-1. PBMCs were treated with 
either LVsh5/C46 or vectors containing the single anti–HIV-1 agents: 
sh5 and C46, and the expression of C46 and downregulation of 
CCR5 by sh5 was confirmed 4 days posttransduction by flow cytom-
etry (Figure 7a). Based on this analysis, transduction efficiency was 
estimated to be 43.7% for LVsh5/C46, 49.4% for C46 alone, 67.5% 
for sh5/eGFP, and 51.7% for eGFP control vector. Transduced PBMCs 
infected with R5-tropic HIV-1 strain NFNSX inhibited viral infection, 
whereas when infected with the X4-tropic strain NL4-3, only cells 
expressing C46 or the dual-therapeutic LVsh5/C46 vector were 
capable of inhibiting HIV-1 infection (Figure 7b). To further test the 
ability of PBMCs to resist HIV-1 infection, cells were transduced with 
LVsh5/C46 at MOI of 5 and reached transduction efficiency of 20–
50%. After 48 hours, the transduced cells were infected with HIV-1 
virus strains, and the level of p24 antigen was evaluated relative to 
control untransduced cells. Results from four independent experi-
ments of cells challenged with the laboratory strains BaL (R5-tropic), 
SF162 (R5-tropic), and Bru (X4-tropic) showed effective inhibition 
of viral replication in all three strains of HIV-1 (Figure 7c) demon-
strating again the potency of LVsh5/C46 to inhibit HIV-1 infection. 
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Clinical isolates of HIV-1 from Clade B and Clade D subgroups were 
tested to further characterize LVsh5/C46-medited viral inhibition. 
Clade B is the most predominant subtype of HIV-1 that is found in 
the developed Western World, whereas Clade D is generally limited 
to East and Central Africa. PBMCs were infected with clinical iso-
late 92US723 (R5/X4 dual tropic, Clade B), and 92UG021 (X4-tropic, 
Clade D), in three independent assays. Infection of LVsh5/C46 modi-
fied PBMCs with Clade B clinical HIV-1 isolate led to an average 
of 83% inhibition of viral replication, whereas 67% inhibition was 
observed with Clade D isolate (Figure 7d). Altogether, these results 
demonstrated that delivery of the dual anti–HIV-1-agents sh5 and 
C46 to hematopoietic cells mediated by the LVsh5/C46 lentiviral 
vector inhibit a broad range of HIV-1 isolates, clades, and tropism.
DISCUSSION
In this preclinical study, we have assessed the therapeutic potential 
of a lentiviral vector (LVsh5/C46) containing two anti–HIV-1 agents 
that target viral entry. We have demonstrated the ability to stably 
introduce LVsh5/C46 into various hematopoietic cells, including 
CD4+ T lymphocytes and CD34+ HSPC, to allow for expression of a 
CCR5-targeted shRNA (sh5) and C46. Treatment of target cells with 
the LVsh5/C46 vector did not show any indication of toxicity. In 
transduced PBMC cultures, cell viability and proliferation were nor-
mal, apoptosis was not induced, and no mark of inflammation was 
observed. LVsh5/C46-treated CD34+ cells maintained their ability 
to differentiate into various hematopoietic lineages with no sign of 
lineage skewing. Moreover, LVsh5/C46-modified cells showed pro-
found resistance to R5-, X4-, and dual-tropic strains of HIV-1.
Gene therapy for HIV-1 relies on genetic modification of hemato-
poietic cells in order to generate long-lasting HIV-1–resistant cells 
that would replenish and stabilize the patient’s immune system. 
Transplantation of manipulated CD4+ T cells would provide a pool 
of T lymphocytes with resistance to HIV-1 infection. A recent study 
by Scholler et al.62 has shown detection of engineered T lymphocytes 
11 years after infusion that suggests modified cells may persist for 
decades, with continued expression and function that may contrib-
ute to prolonged survival. Genetic modification of CD34+ cells would 
generate HIV-1–resistant progenitor cells with the capacity to self-
renew and differentiate into all hematopoietic lineages, including 
CD4+ T cells, macrophages, and dendritic cells, which are the natural 
targets of HIV-1. The general concept is that in HIV-1–infected indi-
viduals, the modified cells, even at low-to-moderate levels of gene 
modification, would have a selective survival advantage over unmod-
ified cells, allowing them to proliferate and expand over time, and as 
a consequence will minimize viral loads and reduce viral reservoirs.
In this work, we transduced T cell lines, PBMCs, and CD34+ HSPC 
to assess toxicity, phenotype, and in the former two cell types pro-
tection from HIV-1. We did not test protection of CD34+ HSPC in the 
present experiments but as a continuation in a humanized mouse 
model (manuscript in preparation).
Figure 6 LVsh5/C46 inhibited R5-, X4-, and dual-tropic HIV-1 infection in Molt4/CCR5 cells. (a) Cells were transduced with LVsh5/C46 at MOI of 5, with 
transduction efficiency of ~80–100%, in three individual experiments. Cells were then challenged with the HIV-1 viral strains BaL (R5-tropic) and NL4-3 
(X4-tropic), and viral replication was measured by p24 antigen. (b) LVsh5/C46-transduced Molt4/CCR5 cells were infected with increasing doses of SF2 
virus (R5/X4) as indicated, and viral replication was determined by p24 protein levels. Results are from one representative experiment. (c) Molt4/CCR5 
were transduced with the indicated lentiviral vectors (sh5, C46, or sh5/C46), followed by infection with BaL strain (R5-tropic) at MOI of 0.2, and p24 
protein levels were assessed 7 and 10 days later. Results are from one representative experiment. (d) Cells were transduced with sh5, C46, or LVsh5/
C46 (sh5/C46) lentiviral vectors at MOIs of 1 and 5 and were challenged with NL4-3 (X4-tropic) or BaL (R5-tropic) HIV-1 viruses. HIV-1 infection was 
measured by p24 protein levels on day 13 postinfection and was compared to untransduced cells. *P = 0.006 compared to untransduced cells. **P = 
0.011 compared to untransduced cells. MOI, multiplicity of infection.
a
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Recent clinical applications using lentiviral vectors for treatment 
of genetic diseases, such as β-thalassemia and adrenoleukodys-
trophy, have also shown these vectors to be safe and efficient.63–65 
A theoretical concern with the safety of lentiviral vector usage is 
the development of RCL. To date, RCL has not been observed in 
any gene therapy clinical trial. LVsh5/C46, as a SIN vector, includes 
modifications designed to contribute to the safety of the vector. 
These features minimize the homology between the vector and 
the HIV-1 sequences, decrease the capacity of RCL formation, and 
reduce the likelihood of mobilization of the vector. Moreover, by 
separating the packaging genes into three plasmids, the number of 
recombination events required to produce a competent replicative 
virus increases. LVsh5/C46 pseudovirus batches did not show any 
evidence for the emergence of replicative particles in transduced 
cells (see Supplementary Table S1). Likewise, integration analysis of 
LVsh5/C46 provirus demonstrated absence of predominant integra-
tion sites (data not shown). Taken together, these data support the 
safety profile of LVsh5/C46 for clinical use.
The stability of the delivered LVsh5/C46 vector into target cells 
was confirmed by southern blot and sequencing analyses, with 
no unforeseen alterations to the genetic elements of LVsh5/C46. 
Splicing of the 812 bp intron within the 5′ UTR of the human UbC 
promoter was well documented previously.58,59 In the present 
study, the spliced UbC promoter was found to be sufficient to drive 
expression of C46 peptide to a detectable level and was effective in 
inhibiting HIV-1 infection.
We have demonstrated efficient delivery of LVsh5/C46 to various 
hematopoietic cells. PBMCs transduced at MOI of 1 resulted in trans-
duction efficiency of ~34% with 1 copy of LVsh5/C46 vector per cell, 
and this level of transduction was sufficient to inhibit HIV-1 in chal-
lenge assays (Figures 1b,d and 7). Based on mathematical modeling, 
we have previously shown that a level of gene marking of ~10–20% 
in hematopoietic stem cells would be sufficient to have a “curative” 
effect, i.e., impact on viral load and CD4+ lymphocyte counts.66 For 
large-scale studies, an MOI of 1 for CD4+ T lymphocytes and MOI of 
5 for CD34+ HSPC were chosen as the optimal doses, with the ideal 
of a therapeutic target of <5 copies of LVsh5/C46 per cell (Figure 3a).
Expression of the integrated LVsh5/C46 transgenes C46 and sh5 
in cells over time was examined in the T cell line CEM.NKR.CCR5 
(Figure 1c), due to the difficulties of maintaining primary cultures 
for extended period of time in culture. These results suggest that 
coexpression of the two anti–HIV-1 genes has no influence on 
their stability over time. An et al.41 have previously demonstrated 
stable expression of CCR5 shRNA in nonhuman primates for over 
14 months posttransplantation of CD34+ HSPC, and Younan et al. 
have recently shown C46-mediated protection from simian-human 
immunodeficiency virus in a nonhuman primate study transplant-
ing autologous ex vivo modified CD34+ HSPC.67
Various gene therapies have been developed to inhibit HIV-1 
infection by blocking postintegration steps or early steps in 
the HIV-1 life cycle that occur prior to genome integration. 
Preintegration strategies are thought to have an advantage since 
production of HIV-1–resistant cells may lead to selective expan-
sion of these modified cells over infected cells, which could prevent 
Figure 7 LVsh5/C46-modified PBMCs inhibit infection from laboratory 
and clinical strains of HIV-1. (a, b) PBMCs were transduced with the LVsh5/
C46 (sh5/C46), C46 alone, sh5/GFP, or GFP vectors, at MOIs of 0.5, and 4 
days later, transduction efficiency was determined by flow cytometry, 
(a) measuring CCR5 and C46 expression, or CCR5 and enhanced green 
fluorescent protein. (b) Cells were then infected with R5-tropic strain 
NFNSX or X4-tropic NL4-3, at MOIs of 0.02, and p24 protein levels was 
measured to assess HIV-1 replication. (c) PBMCs were transduced with 
LVsh5/C46 (sh5/C46) at MOI of five in four independent experiments, and 
48 hours later were challenged with the HIV-1 laboratory strains BaL (R5-), 
SF162 (R5-), or Bru (X4-tropic) at MOIs of 0.14, 0.16, and 0.17, respectively. 
Four days postinfection, p24 levels were assessed and plotted relative 
to untransduced cells (this was done due to high variability between 
experiments and donor variability). Average p24 readings were: 
untransduced-BaL: 134,935 ng/ml (SE: 80,245)/transduced-BaL: 
24,159 ng/ml (SE: 5,665). Untransduced-SF162: 72,153 ng/ml (SE: 
30,041)/transduced-SF162: 20,121 ng/ml (SE: 6,181). Untransduced-
Bru: 106,066 ng/ml (SE: 39,585)/transduced-Bru: 19,371 ng/ml (SE: 
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of 5, and 48 hours later were challenged with the HIV-1 clinical isolates 
92US723 (R5/X4-tropic, Clade B) or 92UG021(X4-tropic, Clade D) in three 
independent experiments. Viral infection levels were determined relative 
to untransduced cells. Average p24 levels were: untransduced-92US723: 
94,986 ng/ml (SE: 60,533)/transduced-92US723: 20,148 ng/ml (SE: 
15,764). Untransduced-92UG021: 45,804 ng/ml (SE: 16,988)/transduced-
92UG021: 15,536 ng/ml (SE: 9,401). GFP, green fluorescent protein; MOI, 
multiplicity of infection; PBMC, peripheral blood mononuclear cell.
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establishment of chronic HIV-1 infection and limit the viral reservoir. 
Entry inhibitors also have the potential to prevent the generation 
of escape mutants in the treated cells, a process that occurs during 
reverse transcription.68 Previous computational modeling studies 
have demonstrated that inhibition of preintegration steps is more 
likely to provide more effective outcomes.69–72
CCR5 is the predominant coreceptor used by HIV-1 during both ini-
tial infection and subsequent infection.73,74 The “Berlin patient” case 
has provided evidence that knocking down CCR5 expression has the 
potential to cure HIV-1. Currently, a gene therapy trial using CCR5 zinc 
finger nuclease is being conducted, and preliminary results indicate 
that treatment is generally well tolerated.75,76 Despite the promising 
results obtained with CCR5 knockdown, these strategies do not pro-
tect against X4-tropic HIV-1 or dual R5/X4 tropisms, which emerge 
with disease progression.21,77 For that reason, a dual-therapy design 
has been chosen in which CCR5 shRNA sh5 and the membrane-
anchored C46 peptide have been engineered into a single lentiviral 
vector. C46, shown previously to effectively inhibit a broad range of 
viral isolates, was the first HIV-1 entry inhibitor to be tested in a clini-
cal trial and was found to be safe with no major toxicities.47 Recently, 
Kimpel et al.78 have evaluated three leading genetic strategies for 
their potency to inhibit HIV-1 replication and demonstrated C46 to 
be the most robust in HIV-1 inhibition in T cells compared to tat/rev 
shRNA and RNA antisense against HIV-1 envelope. The combinatorial 
therapy of CCR5 shRNA and C46 peptide was found in this study to 
have a potentially synergistic effect on HIV-1 inhibition compared to 
the function of the singular genes (Figure 6c,d), which is supported 
by previous studies using a similar combinatorial approaches.79 
Although lentiviral vectors expressing sh5 alone or C46 alone were 
able to protect PBMCs against R5- or X4-tropic HIV-1 (respectively), 
this effect was observed only at a low level of infection, as indicated 
by the level of p24 protein in control cells (Figure 7b). When infec-
tion levels were high, the dual-therapeutic vector displayed the most 
prominent inhibition of HIV-1 replication (Figure 6c,d).
LVsh5/C46 has also been characterized for safety and 
efficacy in vivo using a variety of humanized mouse models. 
During a GLP pharmacology/toxicology study, LVsh5/C46-modified 
human CD34+ HSPC transplanted into NSG mice displayed normal 
hematopoietic engraftment and differentiation that included a 
safe vector integration site profile; also, a humanized bone mar-
row–liver–thymus (BLT) mouse model study supported the abil-
ity of LVsh5/C46-modified hematopoietic cells to protect CD4+ T 
cells from HIV-1 pathogenesis in vivo and reduce viral load within 
peripheral blood and tissues (manuscript in preparation).
Taken together, the preclinical safety and efficacy studies pre-
sented herein, LVsh5/C46 vector is now being evaluated in a phase 
1/2 clinical trial in which autologous hematopoietic cells are trans-
duced ex vivo, followed by infusion back into HIV+ subjects (Clinical 
Trials NCT01734850). LVsh5/C46 anti–HIV-1 genes are designed to 
protect not only the mature T lymphocyte and macrophage popu-
lations but also the HSPC reservoirs that give rise to those progeny 
cells. This is the first clinical trial using RNA interference to down-
regulate CCR5 expression in combination with the fusion inhibitor 
C46 peptide in T cells and HSPC.
MATeRIAlS AND MeTHODS
Cell isolation and culture
Human primary PBMCs. Buffy coats were obtained from healthy do-
nors from the Australian Red Cross Blood Service. PBMCs were iso-
lated from buffy coats by Ficoll Paque Plus (GE Healthcare, Uppsala, 
Sweden, #17-1440-02) density-gradient centrifugation, and the iso-
lated cells were cultured in RPMI (Life Technologies, Carlsbad, CA, 
#72400047) supplemented with 20% fetal bovine serum and PHA-P 
for 48 hours. On the day of transduction, 10 U/ml rhIL-2 was added.
CD4+ cells. CD8+ cells were depleted from isolated PBMCs via CD8 microbe-
ads (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-045-201) and a Var-
ioMACS separator (Miltenyi Biotec). CD3+ T lymphocytes were positively se-
lected and isolated by CD3/CD28-CTS beads (Life Technologies, #402.03D). 
The CD4+/CD3+ lymphocytes were then cultured for 48 hours with the CD3/
CD28 beads in X-vivo 15 serum-free media (Lonza, 04-744Q) supplemented 
with 20 mmol/l HEPES (Life Technologies, #15630106), 5% fetal bovine se-
rum (Life Technologies, 10099141), and 100 U/ml rh IL-2 (Roche, Mannheim, 
Germany #1147528001). Cells were transduced overnight on RetroNectin 
(TaKaRa, Japan, #T100B) coated plates at various MOI, as indicated in the 
experimental methodology.
CD34+ cells. Primary human CD34+ HSPC were purchased commercially 
from AllCells; cells were directly isolated from granulocyte colony-stimulat-
ing  factor (Neupogen) mobilized peripheral blood apheresis products with 
a CliniMACS instrument and CD34+ microbeads (Miltenyi Biotec) according 
to manufacturer’s specifications. Purified CD34+ HSPC were prestimulated 
overnight in 50 ng/ml each of SCF, TPO, and Flt3L (R&D Systems, Minne-
apolis, MN #255-SC, #288-TP, and #308-FK) and transduced on 2.5 mg/cm2 
RetroNectin-coated plates.
Molt4/CCR5 and CEM.NKR.CCR5 cell lines. Cells were cultured in RPMI supple-
mented with 10% fetal bovine serum. Molt4/CCR5 cultures were also sup-
plemented with 1 mg/ml geneticin (Life Technologies, #10131-035).
HEK293T cell line. These cell lines were used for viral production and were cul-
tured in Dulbecco’s Modification of Eagles Medium and 10% fetal calf serum.
LVsh5/C46 plasmid construction
To clone LVsh5/C46 (Cal-1) lentiviral plasmid, the FG12 plasmid31 was first 
modified by adding multiple cloning sites to generate the FG11 plasmid.36 
The membrane-anchored C46 sequence (containing a signal peptide, 
the C46 peptide, a hinge, and a membrane-spanning domain)43 was then 
cloned into BamHI/EcoRI sites within the FG11 plasmid downstream of 
the UbC promoter to produce FG/C46. The FG/C46 plasmid was digested 
with NdeI/XhoI, leaving a fragment of 7.5 kb, containing the UbC promoter 
and the C46 peptide. Next, the FG12 H1shRNACCR5 lentiviral vector41 was 
digested with NdeI/XhoI, and the 2.4 kb fragment, containing the human 
H1 RNA polymerase III promoter and CCR5 shRNA (1005) sequence was 
ligated into the same sites of FG/C46.
Lentiviral vector production and transduction
To produce pseudotype virus, the lentiviral SIN vectors were cotransfected 
with three helper plasmids: gag/pol helper plasmid, the HIV-1 Rev plasmid, 
and the VSV-G envelope plasmid. The four-plasmid system was transfected 
into HEK293T cells by calcium phosphate method (Clontech, Mountain View, 
CA), as described previously.80  For small-scale production, virus-containing 
media (VCM) was collected 24 and 48 hours posttransfection and pooled. 
VCM was concentrated by ultracentrifugation (25,000 rpm) over a 20% 
sucrose solution. Large-scale virus was produced in a manufacturing facility 
under either GLP or GMP conditions, based on a method published previ-
ously.81 VCM was purified by Mustang Q followed by concentration using 
tangential flow filtration filters.
Lentiviral vectors were diluted (1/8–1/512 for unconcentrated samples or 
1/10–1/30,000 for concentrated samples), and 1 ml used to transduce 1 × 105 
293T cells in a 12-well plate. Seventy-two hours posttransduction, cells were 
analyzed for enhanced green fluorescent protein expression or stained with 
2F5 for cell-surface expression of C46. Samples were transduced in duplicate.
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MOI was calculated by dividing the number of virus particles by the  number 
of cells.
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RCL detection
RCL rapid analysis was performed on the large-scale GLP and GMP viral pro-
duction batches made by Indiana University Vector Production Facility. The 
assay was modeled on guidelines recommended by the US Food and Drug 
Administration for detecting replication-competent retrovirus. In the ampli-
fication phase, a test sample of concentrated LVsh5/C46 lentiviral vector, 
representing 5% of the total volume, was used to inoculate a cell line C8166-
45 (derived from human umbilical cord blood lymphocytes). The inoculated 
cells were cultured for a minimum of 21 days to allow potential amplification 
of any RCL, and the supernatant was collected. In the indicator phase, fresh 
C8166-45 cells were infected with the supernatant from the amplification 
step and passaged for 7 days. At the end of this phase, supernatants and 
genomic DNA were collected for ELISA and PCR, respectively. Presence of 
RCL in the test sample was indicated by detection of p24 antigen in the indi-
cator cell supernatants and psi-gag sequences in indicator cell DNA61.
In the coculture, RCL assay postproduction cells were used as a test sam-
ple. 1 × 108 of HEK293T cells that were used to produce the two batches of 
the GMP LVsh5/C46 vector were cocultivated with C8166-45 cells, followed 
by the amplification and induction phases as described above to detect RCL.
Viral isolates
NL4-3 and NFNXS were prepared by calcium phosphate transfection of 293T 
cells with either NL4-3 or NFNXS plasmid DNA. VCM was collected 72 hours 
posttransfection, and aliquots stored at −80 °C.
BaL, SF162, Bru, 92UG021, and 92US723 were prepared by infecting cell-
free supernatant from PBMCs onto fresh uninfected PBMCs in the presence 
of 8 µg/ml Polybrene. Infections were performed over 2–2.5 hours with gen-
tle rocking, followed by one wash of the cells and culture in RPMI containing 
20% fetal bovine serum and 100 U/ml IL-2. Fresh culture media and PBMCs 
were added from days 7 through 21. Supernatant was collected every 3 days 
from day 14, and aliquots stored at −80 °C.
BaL and SF2 used in Molt4/CCR5 experiments were prepared by infect-
ing PM-1 cells with cell culture supernatant containing either BaL or SF2 in 
the presence of 8 µg/ml Polybrene. Infections were performed over 2–2.5 
hours with gentle rocking. At completion of infection, cells were washed 
once and put into culture. Fresh media and PM-1 cells were added from days 
7 through 21. Supernatant was collected every 3 days from day 14, and ali-
quots stored at −80 °C. Titers for all virus batches were determined using 
Perkin Elmer HIV-1 P24 ELISA.
Flow cytometry (FACS)
Up to 1 × 106 cells were transferred to FACS tubes, washed in 1 ml of phos-
phate-buffered saline, and stained with antibodies according to the manu-
facturer’s recommendations. Cells were incubated for 20–30 minutes (room 
temperature or 4 °C), washed in 1 ml of phosphate-buffered saline, and fixed 
in 2% paraformaldehyde for 30 minutes at 4 °C prior to data acquisition on 
an LSRII (Becton Dickinson, San Jose, CA) using FACS Diva software. Data 
were analyzed using FlowJo Software (TreeStar, Ashland, OR). As controls, 
unstained samples and/or relevant isotype control antibodies were used.
For C46 peptide expression, cells were stained for 30 minutes with 1 µg 
2F5 (Polymun Scientific, Klosterneuburg, Austria, #AB001), a monoclonal 
antibody directed against HIV-1 gp41, conjugated to PE using a Zenon PE 
Human IgG1 labeling kit (Molecular Probes, Eugene, OR, Z25455), followed 
by two rounds of signal amplification using a PE-FASER kit (Miltenyi Biotec, 
#130091764). As a control for background fluorescence, untransduced cells 
were stained with 2F5.
For endogenous CCR5 expression, CD195 (APC or PE-Cy7 fluorophores; 
Becton Dickinson) was used for staining. The fluorescently stained cells were 
detected by flow cytometry. Transduction efficiency was determined by cal-
culating the percentage of C46-positive cells.
Evaluation of cell purity. CD4+ cells were stained with CD4, CD3, and CD8 
antibodies (CD4 FITC or PE, CD3 PerCP-Cy5.5 and CD8 PE, Becton Dickin-
son) and analyzed by flow cytometry to calculate the percentage of posi-
tive cells. Purity of CD34+ was determined by using anti-CD34 antibodies 
(Becton Dickinson).
Genomic DNA isolation and real-time quantitative PCR analysis
Genomic DNA from transduced cells was isolated using the Invitrogen 
Purelink Genomic DNA Mini Kit according to the manufacturer’s instruc-
tions. Genomic DNA from each sample (50 ng of genomic DNA per reaction) 
was analyzed using validated qPCR assays to detect C46 transgene 
and β-globin (control gene). Primer and probe sequences for this 
assay are as follows: C46 sense: 5′-CACAGCCTGATCGAGGAGAG-3′; C46 
antisense: 5′ GTCCTGCCACTGGTGGTG-3′; C46 probe: 5′-CACTCCACGCAG 
CACTTCCGCTCG-3′ (5′ 6-FAM, Int ZEN 3′ Iowa Black FQ). β-Globin 
sense: 5′-CAACCTCAAACAGACACCATGG-3′; β-globin antisense: 5′-TCCAC 
GTTCACCTTGCCC-3′; β-globin probe: 5′-CTCCTGAGGAGAAGTCTGCCGTTA 
CTGCC-3′ (5′ TEXAS RED 3′ BHQ-2). Singleplex PCR reactions were set up in 
duplicate in 25 µl reaction volumes using Agilent Brilliant II master mix in a 
96-well plate on the Stratagene Mx3000P real-time PCR platform.
Thermocycling conditions were 50 °C 2 minutes, 95 °C 10 minutes, 40 × 
(95 °C 15 seconds; 60 °C 1 minute).
Data analysis was performed with Stratagene qPCR MxPro software. 
Serial dilutions of LVsh5/C46 plasmid, with known concentration in a 
background of 10 ng/µl genomic DNA, were used to generate standard 
curves. Known amounts of genomic DNA (equated to cell number) was 
serially diluted in H2O to generate a β-globin standard curve; copy num-
ber of C46 transgene was determined from the plasmid standard curve 
and normalized to cell numbers determined using the genomic DNA 
β-globin standard curve.
RNA isolation and RT-qPCRanalysis
C46 RT-qPCR. Total RNA was isolated from cells using Invitrogen Purelink RNA 
Mini Kit according to the manufacturer’s instructions. RNA (20 ng per reac-
tion) was first converted to cDNA using Invitrogen Superscript VILO cDNA 
synthesis kit. Thermocycling conditions were 25 °C 10 minutes, 45 °C 60 min-
utes, 85 °C 5 minutes, 4 °C hold. cDNA was diluted 1:20 and 5 µl added to 
Singleplex validated PCR reactions set up in duplicate in 25 µl reaction vol-
umes using Agilent Brilliant II master mix in a 96-well plate on the Stratagene 
Mx3000P real-time PCR platform.
Taqman primer and probe sequences for this assay are as follows: C46: 5′ 
CACAGCCTGATCGAGGAGAG; C46: 3′ GTCCTGCCACTGGTGGTG; C46 probe: 
CACTCCACGCAGCACTTCCGCTCG (5′ 6-FAM, Int ZEN 3′ Iowa Black FQ).
β2M sense: 5′-GCTGGCGCTACTCTCTCTTTCT-3′; β2M antisense: 5′-GG 
ATGGCGTGAGTAAACCTGAA-3′; β2M probe: 5′-CCTGGAGGCTATCCAGCGTA 
CTCCAAAG-3′ (5′ HEX 3′ BHQ-1).
Thermocycling conditions were 50 °C 2 minutes, 95 °C 10 minutes, 40 × 
(95 °C 15 seconds; 60 °C 1 minute).
Data analysis was performed with Stratagene qPCR MxPro software. 
LVsh5/C46 plasmid with known concentration was serially diluted in a back-
ground of 10 ng/µl total PBMC RNA to generate standard curves. Known 
amounts of total PBMC RNA were serially diluted in H2O, converted to cDNA, 
and diluted in 1:20 in H2O to generate a β2-microglobulin standard curve. 
Copy number of C46 transgene was determined from the plasmid stan-
dard curve and normalized to β2M levels as determined from starting input 
amount RNA to determine relative C46 expression.
sh5 RT-qPCR. Total RNA was extracted using either Qiagen miRNeasy Kit or 
Ambion mirVana miRNA Isolation kit according to the manufacturer’s in-
structions. Extracted RNA (10 ng per reaction) was run in duplicate in Taqman 
custom designed small RNA Assay and microRNA assays to determine the 
relative expression of sh5. cDNA was generated using a Taqman MicroRNA 
reverse transcription kit. Thermocycling was as follows: 16 °C 30 minutes; 42 
°C 30 minutes, 85 °C 5 minutes; hold 4 °C. cDNA was diluted 1 in 5 in nuclease-
free water, and 5 µl added to each custom Taqman PCR assay set up with 
Taqman Universal Master Mix No UNG in 20 µl reactions in 96-well plates on 
the Stratagene Mx3000P. Thermocycling conditions were 50 °C for 2 minutes, 
95 °C for 10 minutes, 40 × (95 °C for 15 seconds; 60 °C for 1 minute).
Standard curves were generated using synthetic RNA Oligos for both sh5 
and RNU38B (control gene used to normalize sh5). RNA Oligos of known 
copy number (107–101) were diluted 10-fold in a background of 10 ng/μl 
tRNA. Data analysis was performed with Stratagene qPCR MxPro software. 
Expression of sh5 was determined from the sh5 standard curve and normal-
ized to RNU38B.
Apoptosis assay
Apoptosis assays were performed using the Caspase-Glo 3/7 Assay (Promega, 
#G8091), measuring caspase-3 and -7 activities, which play key effector roles 
in apoptosis. Cells were transduced overnight on 2.5 µg/cm2 RetroNectin-
coated plates and the following day transferred to 96-well plates at 5 × 104 
cells per well in 100 µl culture volume with three replicates per condition. 
Seven days posttransduction, 100 µl of Caspase-Glo 3/7 Reagent was added 
to each well, and the plates incubated for a further 2–3 hours at room 
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temperature. Luminescence was measured on a Fluostar Optima (BMG 
Labtech, Ortenberg, Germany). As a positive control for apoptosis, cells were 
incubated with 40 µmol/l staurosporine. Fold change in luminescence was 
determined relative to the untransduced control.
Proliferation assay
Proliferation assays were performed using the Premix WST-1 Cell Proliferation 
Assay System (Takara, #MK400), which measures cell proliferation based on the 
enzymatic cleavage of tetrazolium salt (WST-1) to a water-soluble dye that can 
be detected by absorbance at 450 nm. Cells were transduced overnight on 2.5 
µg/cm2 RetroNectin-coated plates, and the following day transferred to 96-well 
plates at 5 × 104 cells per well in 100 µl culture volume with 6 replicates per con-
dition. Seven days posttransduction, 10 µl of Premix WST-1 was added to each 
well, and the plates were incubated for a further 2.5–4 h at 37 °C. Absorbance 
was measured at 450 nm on a Fluostar Optima (BMG Labtech). As a positive 
control for proliferation, cells were incubated with 100 ng/ml rhIL-2. Negative 
controls were culture media alone (blank) and untransduced cells. Fold change 
in absorption was determined relative to the untransduced control.
Inflammation response assay
Inflammation response assays were performed on culture supernatants 
using Quantikine Human IFN-γ ELISA kit (R&D Systems, #DIF50), Quantikine 
Human IL-6 ELISA kit (R&D Systems, #D6050), and VeriKine Human INF-α 
ELISA kit (PBL Interferon Source, Piscataway, NJ #41100). Cells were trans-
duced overnight on 2.5 µg/cm2 RetroNectin-coated plates, and the follow-
ing day transferred to 96-well plates at 5 × 104 cellsper well in 100 µl culture 
volume with 3 replicates per condition. At 7 days posttransduction, superna-
tant was removed from the culture and stored at −80 °C for batching of anal-
ysis. ELISA assays were performed according to manufacturer’s instructions. 
Standard curves for each cytokine to be measured were prepared from the 
standards supplied with the kits. Absorbance at 450 nm was measured on a 
Fluostar Optima (BMG LabTech). Cytokine levels in the sample supernatants 
were read off the standard curve, and fold changes were determined for the 
transduced samples relative to untransduced cells.
HIV-1 challenge assays
HIV-1 challenges on PBMCs were performed by pelleting 5 × 105 cells in 
HIV-1 viral supernatant containing 8 µg/ml polybrene. Cells were then 
incubated at 37 °C for 2–2.5 hours with gentle tapping every 15 minutes. 
Postincubation, cells were washed once and put into cultures of 1.5 ml in a 
six-well plate. The cultures were then sampled for p24 at either day 4 or 6.
HIV-1 challenges on Molt4/CCR5 cells were performed by pelleting 1 × 106 
cells in HIV-1 viral supernatant containing 8 µg/ml Polybrene. Cells were 
then incubated at 37 °C for 2–2.5 hours with gentle rocking. Postincubation, 
cells were washed once and put into cultures of 3 ml per T25. Cultures were 
sampled on days 7 or 8, and 13 or 14, and fresh media added after sampling.
Evaluation of p24 by ELISA assay. p24 was determined by PerkinElmer HIV-1 
p24 ELISA following the manufacturer’s instructions.
Analysis of integrated vector genomes
VERO cells were transduced with GMP-grade LVsh5/C46vector, genomic 
DNA was then isolated, and digested with NotI/Bsu36I and subjected to 
southern blot analysis using an 890 bp probe positioning at the 5′ end of the 
LVsh5/C46 sequence (NotI/PstI). The LVsh5/C46 plasmid, digested with NotI/
Bsu36I, was used as a positive control.
CFU assay
Cells are plated at 500 cells per dish in methylcellulose media (Methylcult 
Optimum, Stem Cell Technologies) to enable colonies to form from indi-
vidual cells. Cultures are incubated in a humidified dish for 14–16 days and 
then scored.
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